Insider · CIK 0001798155
Timothy Keutzer
cooofficer
Files at SPRO (Spero Therapeutics, Inc.). First filing Feb 5, 2025, latest Feb 9, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $193k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRO: Spero Therapeutics, Inc.
SPROOct 9, 2026 · close 1.20
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | SPROsell Spero Therapeutics, Inc. | $44k 18,652 shares | -2% | +332% from low-20% from high | |
| 30Weak | SPROsell Spero Therapeutics, Inc. | $101k 46,586 shares | -6% | +298% from low-27% from high | |
| 28Weak | Spero Therapeutics, Inc. | $3,339 1,695 shares | -0% | +257% from low-34% from high | |
| 26Weak | SPROsell Spero Therapeutics, Inc. | $44k 56,537 shares | -7% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -18,652 | $2.36 | $44k | 742,506 | Feb 9, 2026 |
| Feb 2, 2026 | SPRO Spero Therapeutics, Inc. | AGrant or award Common Stock | +68,000 | $0.00 | $0 | 807,744 | Feb 5, 2026 |
| Feb 2, 2026 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -18,891 | $2.20 | $42k | 788,853 | Feb 5, 2026 |
| Feb 3, 2026 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -24,224 | $2.14 | $52k | 764,629 | Feb 5, 2026 |
| Feb 4, 2026 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -3,471 | $2.24 | $7,775 | 761,158 | Feb 5, 2026 |
| Feb 2, 2026 | SPRO Spero Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +137,000 | $0.00 | $0 | 137,000 | Feb 5, 2026 |
| Aug 28, 2025 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -1,695 | $1.97 | $3,339 | 739,744 | Sep 3, 2025 |
| Feb 3, 2025 | SPRO Spero Therapeutics, Inc. | AGrant or award Common Stock | +266,139 | $0.00 | $0 | 797,976 | Feb 5, 2025 |
| Feb 5, 2025 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -3,974 | $0.78 | $3,100 | 794,002 | Feb 5, 2025 |
| Feb 5, 2025 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -27,643 | $0.78 | $22k | 766,359 | Feb 5, 2025 |
| Feb 5, 2025 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -24,920 | $0.78 | $19k | 741,439 | Feb 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.